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explained variance), followed by hierarchical regression 
and structural equation modeling (SEM). The PCA sug-
gested a one-factor solution, where the latent variable 
showed highest loadings of SCORE risk estimates, triglyc-
erides, depression severity, and pulse pressure. A compre-
hensive SEM was adjusted with 92.7% explained variance: 
overall CVD risk related to depression, pulse pressure, tri-
glycerides, and fasting glucose.
Conclusion The findings in this MetS sample suggest that 
triglycerides and depression severity are the key variables 
among MetS biomarkers in cross-sectionally associating 
with the fatal and total SCORE risk estimates in MetS.
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Abbreviations
MetS  Metabolic syndrome
T2DM  Type 2 diabetes mellitus
BMI  Body mass index
CVD  Cardiovascular diseases
CHD  Coronary heart disease
SEM  Structural equation model
PCA  Principal component analysis
HPA  Hypothalamic pituitary adrenocortical axis
ICD  International Classification of Diseases
IDF  International Diabetes Federation
SBP  Systolic blood pressure
DBP  Diastolic blood pressure
∆BP  Difference blood pressure, pulse pressure
GLM  General linear model
HRA  Hierarchical regression analysis
MVLR  Multi-variable logistic regression
Abstract 
Purpose Triglycerides are considered an emerging risk 
factor for cardiovascular mortality. Recent evidence relat-
ing depression and metabolic syndrome (MetS) implicated 
triglyceride levels. We thus investigated interrelations of 
self-reported depression severity (Zung) and MetS-related 
biological measures with CVD risk estimates in MetS 
patients.
Methods N = 101 patients fulfilling International Diabetes 
Federation criteria for MetS from a nationwide sampled 
treatment cohort for MetS with familial T2DM risk or man-
ifest T2DM in a Ukrainian governmental health care sys-
tem were participants. Both laboratory and non-laboratory 
measures were included. Recent European cardiological 
SCORE system CVD risk estimates were used as outcome 
variables.
Results Following correlation matrix, we entered all vari-
ables into principal component analysis (PCA; 76.7% 
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ANOVA  Analysis of variance
TG  Triglycerides
HDL  High-density lipoprotein
LDL  Low-density lipoprotein
VLDL  Very low-density lipoprotein
MA  Microalbuminuria
TCH  Total serum cholesterol
OLS  Ordinary least squares
ZSDS  Zung Self-Rating Depression Scale
OR  Odds ratio
HR  Hazard ratio
BDI  Beck Depression Inventory
CRP  C-reactive protein
Introduction
There is accumulating evidence for a reciprocal relation 
between depression and elevated triglycerides (TG) level 
[1, 2], in general, and specifically in the context of the 
metabolic syndrome (MetS). Serum TG involvement in 
MetS is herein a key factor, with (a) free fatty acids pro-
moting insulin post-receptor signaling conducive to insulin 
resistance, (b) hepatic overproduction of very low-density 
lipoprotein (VLDL, please refer to list of abbreviations for 
acronyms) and chylomicron residuals, and (c) formation of 
small-dense LDL and HDL particles with high atherogenic 
potential from hepatic triglycerides [3, 4]. MetS is a mul-
ticomponent condition where endocrinologic, nutritional, 
and circulation factors, dependent on genomic-environ-
mental interaction and epigenetic programming, enter with 
increasing age into a mutually degrading spiral, resulting in 
insulin resistance, cardiovascular adverse events, and ulti-
mately also in neurodegeneration.
Stress-related hypothalamic-pituitary adrenocortical 
(HPA) axis over-excitability in MetS contributing to corti-
sol action on metabolic factors has been documented inde-
pendently by several research groups [5, 6]. Accordingly, 
available meta-analyses indicate a notion of bi-direction-
ality [7] between depression and MetS, with longitudinal 
research providing both support for baseline-depression 
bearing risk for MetS [1, 8], and support for baseline-MetS 
bearing risk for depression [2, 9, 10]. Whether plasma 
lipid traits confer risk to cardiovascular events at all is not 
uncontroversial, yet have influential prospective cohort 
studies suggested a role of triglycerides in ischemic cardio-
vascular diseases (CVD) [11, 12].
Genomic and epigenetic studies also point to interactions 
among those respective genomic bases, which are in greater 
probability for expression and translation in the presence of 
adverse contexts in lifestyle, environmental, and person-
ality circumstances [13]. These are, according to current 
results, then more likely to form epigenetic templates for 
factors critical to formation of MetS. For example, there is 
a robust relation between recurrent depression and obesity 
[14], with the consequence of dyslipidemia, type 2 diabe-
tes mellitus (T2DM), and CVD. For example, subsequent 
genomic investigations [15] substantiated an epigenetic 
alteration of FTO gene (16q12.2) polymorphisms, which 
regulate fat mass and obesity, in the context of depression 
recurrence. There is also a substantiated epigenetic feed-
back loop from adiposity to APOA5 and expression of other 
genes in locus 11q23 then influencing levels of plasma lipid 
traits TG, HDL, and LDL [16].
In the present study, we investigated within an observa-
tional national Ukrainian MetS cohort the cross-sectional 
relations of MetS biomarkers with self-reported depres-
sion levels and CVD risk probabilities as assessed with the 
SCORE system of the European Cardiological Society. To 
estimate respective variance proportions and causal interre-
lation, structural equation modeling (SEM) was employed. 
Regarding hypotheses, we generally followed the largely 
replicated observation that depression is a risk factor 
attenuating survival following cardiovascular events. As a 
specific hypothesis, we envisaged a role of serum triglycer-
ides in combination with MetS components and depression 
toward estimation of cardiovascular risk.
Materials and methods
Participants
Volunteering participants were recruited from a national 
pool of MetS patients monitored and treated at specialized 
units at Railway Hospital No. 2 in Kiev following referral 
within the countrywide healthcare system of the Ukrainian 
Ministry of Transport from all parts of Ukraine. Based on 
endocrinologic parameters or family histories (e.g., par-
ents or siblings affected) indicating specific elevated risk 
for T2DM, these patients were annually re-examined and 
treated. Compilation of the final sample N = 101 (mean 
age 45.6 ± 0.14 SEM years; education levels 4.73 ± 0.11, 
4 = junior college level, 67 females) is summarized by 
the flowchart in Fig. 1 illustrating steps with inclusion and 
exclusion criteria.
Sample compilation
Composition and size of the final sample was adapted 
conforming to designs (e.g., [17]) in biomarker detec-
tion studies in MetS, specifically in counterbalancing dia-
betic and non-diabetic patients. The Institutional Review 
Board of the National Medical University of the Ukraine 
had endorsed all procedures. All subjects gave written 
informed consent to the scientific use of their data and were 
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reimbursed for their participation. The investigation was 
conducted in compliance with the Helsinki Declaration 
(www.wma.net/e/ethicsunit/helsinki.htm).
Disease classification
Obesity, hyperinsulinemia, dyslipidemia, and elevated arte-
rial blood pressure, according to ICD-10 criteria, were the 
primary consensus diagnoses independently established by 
at least two staff cardiological and/or endocrinologic spe-
cialists. International Diabetes Federation (IDF; www.idf.
org/publications) MetS criteria were coded from the patient 
files: Indication of MetS was concluded in the presence of 
three or more of the following features: waist circumfer-
ence >80 cm in women and >94 cm in men; fasting serum 
triglycerides ≥1.7 mmol/L, serum high-density lipoprotein 
<1.29 mmol/L in women and <1.03 mmol/L in men; sys-
tolic blood pressure ≥130/85 mm/Hg or treated; fasting 
plasma glucose level ≥5.6 mmol/L or T2DM.
Self‑report
The validated official Russian language version of the 
Zung Self-Rating Depression Scale [18] (ZSDS; www.
dic.academic.ru/dic.nsf/ruwiki/1682956) was used for 
depression self-report. The ZSDS was designed to assess 
clinical depression with 20-item positively or negatively 
worded questions addressing somatic, affective, and cogni-
tive aspects of depression on a four-level Likert-type scale. 
Scores <35 are considered non-depressed; 35–50 mildly, 
50–59 moderately, and >60 severely depressed. Other 
clinical scales were administered for control purposes as 
previously reported [19, 20]. We focus in this report on 
results specifically pertaining to depression levels.
Biological laboratory data
Sitting arterial blood pressure was determined brachially 
by digital oscillometric sphygmomanometer device upon 
hospital admission conforming to clinical standard proce-
dures. Pulse pressure was computed as the difference span 
between SBP and DBP (∆BP). Waist circumference was 
determined by band measure 1 cm above umbilicus level. 
Laboratory analyses of all biological specimens were per-
formed in-house with enzymatic methods using commer-
cially available reagents. The laboratory of Railway Hos-
pital No. 2 was subject to quality control standards (e.g., 
round robin tests) imposed by the Ukrainian Ministry of 
Public Health and was certified accordingly.
Establishment of cardiovascular risk variables
Cardiovascular risk estimation was performed based on 
2011–2012 criteria of the European Cardiological Soci-
ety (http://www.escardio.org/guidelines) [21]. The vari-
ables individual CVD risk, SCORE fatal risk, and SCORE 
total risk were established following the instructions. The 
SCORE system was used with Ukraine classified as a 
CVD high-risk country. Likewise, following instructions, 
the variable individual CVD risk was computed by sta-
tistical aggregation of seven components. Risk levels for 
total cholesterol, HDL, LDL, VLDL, Friedewald fraction, 
Fig. 1  Flowchart for patient 
sampling and exclusion steps. 
Note The final sample in statisti-
cal analyses was N = 101
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triglycerides, etc., were based on 2002 National Institute of 
Health (NCEP III) criteria and 2013 American College of 
Cardiology/American Heart Association cholesterol guide-
lines [22–24] (S1 Supporting Text for more details).
Statistical methods and models
Using the recommended standard textbook approach [25], 
we examined the data in the steps correlation, PCA, HRA, 
and SEM. The SEM module in STATA, which is based on 
the Bentler–Weeks regression approach [26, 27] to decom-
posing variance–covariance matrices, employs the maxi-
mum likelihood statistics in fitting observed information 
matrices (OIM) with the Newton–Raphson stepping algo-
rithm. Our overall SEM approach was the specification of 
a measurement-based causal model, with using the latent 
construct indicated by the one-factor solution for over-
all CVD risk in the preceding PCAs. Error terms were 
included to estimate measurement error for both observed 
and latent variables. Following detection of skewness in all 
three outcome risk variables, these were treated for GLM 
analyses by log-10 transformation in SPSS (see S1 Sup-
porting Text and S5&6 Supporting Tables 2&3).
STATA®/MP 12.1 (64-bit version; StataCorp LP, Col-
lege Station, TX, USA) was used for the statistical meth-
ods hierarchical regression analysis (HRA), multivariable 
logistic regression (MVLR), and structural equation mod-
eling (SEM). IBM SPSS 20 for Intel Macintosh comput-
ers (IBM Corp, Armonk, NY, USA) was used to compute 
correlations, analyses of variance (ANOVA), and principal 
components analysis (PCA).
Results
Scale reliability and confounds of the depression 
measure
The internal consistency for the ZSDS, as ascertained by 
Cronbach’s coefficient α = 0.824, was satisfactory for 
further analyses and well in line with previously reported 
psychometric properties for this instrument. Examina-
tion for confounds of ZSDS revealed that family size (i.e., 
number of persons actually cohabitating, but not the num-
ber of children) was significantly associated with greater 
depression (r = 0.252). Females (M = 46.36 ± 1.028 
SEM) had significantly severer depression (t = −2.738, 
df 80.42, p = 0.008, 95% CI 7.323–1.158) than males 
(M = 42.12 ± 1.159 SEM). Significant relations with 
depression severity were also found for height (r = 0.201) 
and waist girth (r = 0.347). All other sociodemographic 
and anthropometric measurements were unrelated (rs < 0.2) 
to depression severity. The range of ZSDS distribution 
depression severity of this sample (S6 Supporting Fig-
ure 2) with a prevalence of ZSDS scores >35 but remaining 
<60 indicates that the majority in this sample suffers from 
depression in a mild to moderate strength. Higher depres-
sion ranges are missing in this sample in accordance with 
exclusion criteria (such higher ranges would have indicated 
severe psychopathology).
Examination of laboratory and risk variables
Descriptives of all basic study variables are listed (S4 Sup-
porting Table 1). Significant direct associations for biolog-
ical variables were observed for SBP (r = 0.199), pulse 
pressure (r = 0.239), blood pressure risk (r = 0.269), 
trend toward significance were present for Friedewald 
fraction (r = 0.143) and serum triglycerides (r = 0.143). 
Testing for correlation with all other risk variables includ-
ing microalbuminuria, fasting glucose, total cholesterol, 
HDL, LDL, and VLDL was insignificant. Of outcome 
risk variables, zero-order correlations were significant 
for the latent variable CVD risk (r = 0.223), and for 
computed individual CVD risk. All other risk variables 
remained insignificant in association with ZSDS, but 
exhibited strong inter-correlations (rs 0.634–0.967, all 
ps < 0.0001). Sociodemographic confounds for biologi-
cal variables were rare: Family size was a confounder with 
Friedewald (r = 0.215), blood pressure risk (r = 0.248), 
and triglycerides (r = 0.217); education level with triglyc-
erides risk (r = −0.217); number of children with HDL 
(r = −0.216). Systematic confounds were present for all 
outcome risk variables individual CVD risk, fatal SCORE, 
total SCORE, and latent variable CVD risk, with age (rs 
0.608–0.809, all ps < 0.0001), family size (rs 0.193–0.350, 
all ps < 0.05), and number of children (rs 0.213–0.263, all 
ps < 0.05). All other correlations were insignificant. Group 
differences with respect to clinically depressed status (S6 
Supporting Table 3) and diabetic status (S5 Supporting 
Table 2) revealed that outcome variables exhibit sensitivity 
toward the respective clinical status.
Preparatory analyses
PCA, ANOVA, HRA, and MVLR models were tested in 
preparation of SEMs, as suggested by standard approaches. 
The results of these analyses are reported in the S1 Sup-
porting Text file linked to this article. The profile plots 
of the ANOVAs for sex differences in disease severity of 
MetS are depicted in S2 Supporting Figure 1. In the result-
ing one-factor solution was the main latent component 1 
dominated by combined CVC risk (S7 Supporting Table 4). 
Testing the factor loadings systematically by HRA and 
MVLR models corroborated the findings in the PCA 
(results reported in S1 Supporting Text).
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Structural equation modeling
The aim of the SEM was the setup and testing of a parsi-
monious causal model with less than ten paths. Steps in 
SEM included the setup of measurement-based regres-
sion path models, and the inclusion of one latent variable 
(being both exogenous and endogenous), as suggested by 
the one-factor solution in PCA (i.e., a one-factor causal 
model). We tested several part models with both relaxed 
and constrained errors, inclusion of only single outcome 
risk variables, and with and without adjustment to sex 
and comorbidities. Although we could obtain valid and 
stable models, overall percentage of variance explanation 
remained in ranges R2 = 0.461–0.533. The best fitting 
solution was obtained with a model (a) containing sex as 
an observed variable, (b) including all three outcome CVD 
risk variables, (c) including adjustment to comorbidi-
ties. This final comprehensive SEM is depicted in Fig. 2, 
with Table 1 reporting path coefficients and their signifi-
cances, and Table 2 reporting equation-level goodness-
of-fit indices. This constrained model with adjustment of 
standard errors to differential clustering in comorbidities 
yielded an overall unique variance explanation of 92.7% 
in robust OLS path estimation. The adjusted model was 
distinctly superior to all other solutions (additional infor-
mation S1 Supporting Text). Please note that none of the 
traditional SEM goodness-of-fit criteria are reported by 
STATA in robust estimation. In conclusion, we can state 
that, out of our computations, the extended and adjusted 
model yielded best fit, as indicated by the Bentler–Raykov 
squared multiple correlation coefficients, and the magni-
tudes in the prediction-correlations (Table 2).
Fig. 2  Diagram of comprehensive SEM. Zung depressivity score, 
Ind Risk individual CVC risk index, SCORE_t total CVD risk index, 
SCORE_f fatal CVD risk index, ε1–8 error variances, a–r path indica-
tors (see Table 2)
Table 1  Comprehensive structural equation model: path estimation
a Maximum likelihood estimation, 12 iterations; log pseudolikelihood −364.2662
Code Path Coefficient Standard error Z P 95% CI lower 95% CI upper
a Individual risk → main component 0.141 0.0154565 9.17 0.000 0.111 0.171
b SCORE fatal → main component −2.945 0.2305982 −12.77 0.000 −3.397 −2.493
c SCORE total → main component 3.287 0.1515965 21.69 0.000 2.990 3.584
d Main component → subject sex 0.453 0.0479932 9.45 0.000 0.359 0.547
e Main component → family size 0.309 0.0408251 7.59 0.000 0.229 0.389
f Main component → Zung depression score 0.540 0.0312704 17.28 0.000 0.479 0.601
g Main component → triglycerides 0.427 0.0326967 13.09 0.000 0.363 0.492
h Main component → microalbuminuria 0.071 0.0097205 7.29 0.000 0.052 0.089
i Main component → pulse pressure 0.551 0.0617042 8.94 0.000 0.431 0.672
j Main component → fasting plasma glucose 0.364 0.0305370 11.92 0.000 0.304 0.423
k ε1 error main component 0.073 0.0630226 – – 0.013 0.395
l ε2 error subject sex 0.794 0.0435319 – – 0.713 0.884
m ε3 error family size 0.904 0.0252976 – – 0.885 0.954
n ε4 error Zung depression score 0.707 0.0338024 – – 0.644 0.777
o ε5 error triglycerides 0.816 0.0279834 – – 0.763 0.873
p ε6 error microalbuminuria 0.994 0.0680616 – – 0.992 0.997
q ε7 error pulse pressure 0.695 0.0222248 – – 0.825 0.912
r ε8 error fasting plasma glucose 0.073 0.0630216 – – 0.013 0.395
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Discussion
The main findings of this study are that, as SEM suggests, 
overall CVD risk in MetS is associated with an ensemble 
of single biomarkers (triglycerides, microalbuminuria, 
fasting glucose level, pulse pressure), single sociodemo-
graphic markers and mid-range depression. The results of 
this study specifically highlight the role of triglycerides 
in dyslipidemia associated with self-reported depression 
level as contributing to overall CVD risk in MetS with 
29.3% explained variance accounted for. With respect to 
hypothesis testing, the results in this MetS sample provide 
further support for manifold findings that depression level 
is predictive for CVD-related mortality (here indicated 
by SCORE fatal estimates). In this sample, the pattern of 
cross-sectional association is such that triglycerides rather 
than the other lipid traits (cholesterol fractions) exerted 
the major risk contributing 18.3% to overall CVD risk of 
92.7%. As triglycerides are still seen as an “emerging risk 
factor” (NCEP III guidelines of 2002, ESC guidelines of 
2012), this finding provides relative novelty to respective 
accumulating evidence.
Regarding the relation of depression and mortality, 
there are consistencies with published literature in this 
respect. There is an increased risk for mortality (OR 1.5) 
[28] according to the recent meta-analyses, where CVD 
is among the main causes of mortality associated with 
depression. Also, for a relation of depression symptoms 
and dyslipidemia there is replicated support. A recent Finn-
ish longitudinal developmental study spanning preschool 
measurement with adulthood indicated that trajectories of 
steep increases in triglycerides were predictive of depres-
sion onset [29]. One prospective study in congenital heart 
disease for major adverse cardiovascular events (fatal and 
hospitalization incidences) related to depression indicated 
ORs 1.6–3.6 for a 5-year period [30]. The cross-sectional 
fatal SCORE risk in a Finnish regional study for depression 
was OR 2.9 for males and OR 1.3 for females with 30% 
of MetS prevalence [31]. In myocardial infarction survi-
vors increases depression onset the longitudinal risk for 
subsequent cardiovascular adverse events at a HR 1.7, with 
proportional higher risk for more depressed patients [32]. 
Also, for stroke, moderate depression assessed with ZSDS 
resulted in independent risks (ORs 1.9–2.7) [33]. Likewise, 
in a Dutch 10-year longitudinal study, BDI depression 
scores rather than actual clinical depression, proved as a 
better independent predictor, with HR 3.9 for cardiac mor-
tality and 1.7 for non-fatal cardiac events [34].
Also in healthy individuals is depression (ZSDS) asso-
ciated with inflammation marker C-reactive protein (CRP), 
leukocytes, and fibrinogen, as a regional Greek study found 
[35]. In stable CHD patients proved ZSDS a better predic-
tor at OR 1.1 of later adverse cardiovascular events than 
CRP baseline levels, also in a Greek two-step study [36]. 
In all studies, depression is found an independent predic-
tor of CVD risk, but MetS components such as diabetes or 
abdominal obesity also form significant interactions [37]. 
Psychosocial stress and depression (ZSDS) have associa-
tions with different biomarkers, but triglycerides may be a 
linking variable: in an Italian study, depression correlated 
with triglycerides, which were also associated with stress 
scores [38].
The best supported explanatory mechanism for the ele-
vated CHD risk in depression is a dysregulated HPA axis, 
involving sympathetic overstimulation and hypercorti-
solemia [39]. HPA dysfunction and MetS criteria were more 
prevalent in the melancholic subtype of clinical depression 
[40]. Reduction in telomere length as a result of stress is 
associated both to single MetS components, including tri-
glycerides, and also progression into MetS constellation 
[41]. In structural neuroimaging, volume reduction in the 
nucleus globus pallidus correlated both with MetS severity 
and depression severity, thus providing a putative brain cor-
relate of MetS [42] (S1 Supporting Text).
Table 2  Equation-level 
goodness-of-fit indices
mc correlation between the dependent variable and its prediction, mc2 the Bentler–Raykov squared multiple 
correlation coefficient. Stability analysis yields a stability index = 0: SEM satisfies stability condition
P value tested against random permutation
Dependents Fitted Predicted Residual R2 mc mc2 Wald-χ2 df P
Subject sex 0.181 0.372 0.143 0.206 0.453 0.205 – – –
Family size 1.342 0.129 1.213 0.095 0.309 0.095 424.09 1 0.0000
Zung depression score 86.991 25.412 61.578 0.293 0.540 0.292 769.79 1 0.0000
Triglycerides 0.675 0.123 0.551 0.183 0.428 0.183 1130.25 1 0.0000
Microalbuminuria 0.195 0.001 0.195 0.005 0.071 0.005 84.85 1 0.0000
Pulse pressure 132.074 40.188 91.936 0.304 0.551 0.304 511.55 1 0.0000
Fasting plasma glucose 4.053 0.536 3.516 0.132 0.363 0.132 1937.60 1 0.0000
Main component 0.037 0.034 0.003 0.926 0.962 0.926 1074.60 3 0.0000
Overall 0.927
J Endocrinol Invest 
1 3
One strength of this study lies in countrywide sampling 
and the high level overall explained variance in SEM. The 
current study is limited due to its sample size and cross-
sectional design, albeit provides robust statistical effects. 
Further limitations lie in the non-inclusion of direct neu-
roendocrine measurement and lack of genotype control.
Conclusion
This study presents evidence in support of the hypothesis 
that levels of triglycerides play a major role in overall CVD 
risk in MetS. Manifold evidence has long described depres-
sion, CVD-related mortality in the context of MetS symp-
toms as long-term consequences of dysregulated HPA. 
The present findings add to these postulates by estimating 
risks and showing patterns of association cross-sectionally. 
Future studies should use prospective design and be con-
trolling for genotype and indices of signaling in neuroendo-
crine pathways in question.
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